Hck-IN-3

Hck-IN-3 is an orally effective inhibitor targeting HCK with a KD of 3.92 μM. It suppresses the release of NO and exhibits an IC50 of 6.52 μM in RAW264.7 cells. Hck-IN-3 inhibits the release of TNF-α, IL-6, and IL-1β in a concentration-dependent manner. Additionally, it downregulates the protein expression of NLRP3, ASC, pro-caspase-1, and pro-IL-1β, also dependent on concentration. Hck-IN-3 is applicable for research into acute and non-injury related inflammatory diseases.